Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Zone & Co Strengthens Leadership Team with Two Key Executive Appointments to Drive the Next Stage of Growth

Published

on

zone-&-co-strengthens-leadership-team-with-two-key-executive-appointments-to-drive-the-next-stage-of-growth

BOSTON and AMSTERDAM and SYDNEY, April 3, 2024 /PRNewswire/ — Zone & Co, the leading provider of ERP-native software solutions for the CFO’s office, today shares the extension of its executive team with two seasoned tech-leaders: Chad Wonderling as Chief Financial Officer and Jessica Garrett as Chief Marketing Officer.

Both Wonderling and Garret bring close to two decades of experience in their respective domains at high-growth technology organizations, accelerating Zone’s ability to capitalize on its global momentum and drive industry leading innovations for managing back-office operations at scale.

Wonderling joins Zone with a history of leadership roles at pre- and post-IPO high-growth companies, most recently from Salesloft where he served as its Chief Accounting Officer. Garrett is an award-winning technology-marketing leader, who brings deep experience building out and leading revenue-driving global marketing organizations for both high-growth scale-ups and enterprise-level brands.

“We’re thrilled to have Jessica & Chad on board to help drive our next phase of growth and accelerate our ability to help transform back-office operations,” said Thomas Kim, CEO at Zone and Co. “Their track record in helping tech companies scale profitably while investing in a strong and open team culture will be immensely valuable in continuing to evolve our organization and to increase the visibility of and engagement with our platform globally.”

Prior to Zone, Wonderling spent five and a half years at Salesloft where he contributed to its exponential revenue increase, the Series D and E funding rounds, and a majority stake investment by Vista Equity Partners at a valuation of $2.3 billion. As Vice President & Corporate Controller at Rubicon Technologies, he was responsible for the company’s financial operations, financial reporting, treasury, and corporate development and acquisition integration, while influencing global expansion and growth. He also served as Corporate Controller & Head of Finance at the publicly traded company Ceres Global Ag (TSX:CRP) where he helped lead the revenue growth from approximately sub-$30 million to nearly $500 million.

“I’ve been fortunate to be part of several rapidly growing companies in my career, and the finance function can play a pivotal role in an organization,” said Wonderling, who is also a former customer of Zone. “Having purchased and used Zone’s solutions, I’ve realized the power they can provide firsthand. I look forward to being part of Zone’s growth story, and helping our customers’ finance, HR, and operations teams play an instrumental role in driving their growth.”

Garrett, who most recently served as Chief Marketing Officer at Cloud Academy, is a strategic and growth-oriented tech-marketing leader known for her ability to build high-performing, customer-focused, and data-driven marketing teams. During her 26 years of experience in driving growth and transformation across global tech organizations, she has repeatedly helped propel companies from $50M$300M revenue growth, break into new markets with best-in-class CAC:LTV ratios, stand up new enterprise-class GTM motions for deep market penetration, and launch award-winning brand strategies.

“I am thrilled to join this visionary team at such a pivotal moment,” shares Garrett. “Our company’s trajectory is unmistakable, and I am eager to leverage our unique value proposition to captivate audiences and drive dominating growth. Zone’s commitment to transform the finance, HR and operations functions in an end-to-end way and ability to push the boundaries of out-of-the-box ERP software with such a strong and relevant portfolio, has resulted in impressive momentum that I’m excited to help capitalize on. We’ve only scratched the surface of its market potential and I look forward to helping unlock marketing-led growth.”

The addition of Wonderling and Garrett comes less than a year following the appointment of Thomas Kim as Chief Executive Officer in April of 2023. Under Kim’s leadership, the company experienced nearly 50% growth in 2023, welcomed over 1,500 new customers across Europe, Australia and North America all while expanding its partner-ecosystem and driving towards its overall platform strategy.

Zone also enhanced its portfolio with a new Payroll solution, introduced self-service implementation for its AP automation solution to reduce time-to-value with 50%, and is continuing to roll-out industry leading AI-capabilities across products, working towards a 99% decrease in manual data entry in key finance workflows.

About Zone & Co
The Zone platform is designed to help companies across industries scale, adapt and comply with ease, through forward-thinking cloud-solutions that revolutionize back-office operations. Built as native extensions of user’s cloud-ERP instances, the software effectively enhances its out-of-the-box capabilities and efficiencies, maximizes platform value and prevents data disparity. With solutions for complex billing & revenue recognition, advanced reporting, AP automation, Payroll and more, Zone allows finance, HR and operations professionals to integrate the entirety of order-to-cash, procure-to-pay, record-to-report and other critical back-office workflows with a single login. The company serves over 3,000 customers worldwide with an international team across hubs in Europe, North America, Australia and Asia.

To learn more, please visit: www.zoneandco.com or follow us on LinkedIn: linkedin.com/company/zoneandco.

Photo – https://mma.prnewswire.com/media/2377919/Zone_Company_Software_Chad_Wonderling_CFO_and_Jessica_Garrett_CMO.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/zone–co-strengthens-leadership-team-with-two-key-executive-appointments-to-drive-the-next-stage-of-growth-302107023.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

on

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

on

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

on

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Continue Reading
Advertisement
Advertisement

Latest news

Trending